Study to evaluate the product flow, breakdown and elimination of DOTAREM from the blood and its safety and efficacy in children aged > 2 years

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003215-21

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate pharmacokinetics profile in plasma of DOTAREM following single intravenous injection in pediatric subjects aged up to 23 months (inclusive)


Critère d'inclusion

  • Pediatric subject aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced Magnetic Resonance Imaging of any body region